T-DXd, a next-generation ADC, comprises a HER2-targeting monoclonal antibody linked to the cytotoxic payload deruxtecan via a stable linker, enabling targeted delivery to HER2-expressing tumor cells. The gene discussed is ERBB2; the disease is neoplasm.